Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & amp; MRD
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from the 1st European Myeloma Network (EMN) Meeting, in Turin, It... Author: VJHemOnc Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Predicting long-term outcomes in myeloma: MRD
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses new strategies for clinical trial design in multiple myeloma (MM). Prof. McCarthy highlights measurable residua... Author: VJHemOnc Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

How to treat high-risk mutated myeloma
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses considerations in the treatment of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in... Author: VJHemOnc Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Transplant trials in myeloma: EMN02 and BMT CTN 0702
Philip McCarthy, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses two Phase III multiple myeloma (MM) transplantation studies that have been performed: EMN02 (NCT01208766) and B... Author: VJHemOnc Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

Advances in the classification of agressive myeloma
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses advances in the classification of high risk multiple myeloma (MM) from the 1st European Myeloma Network (EMN) Meeting, in ... Author: VJHemOnc Added: 08/16/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24 trials
Yung Lyou, MD, UC Irvine Health, talks about 3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24 trials at ASCO 2018 Author: moasc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

3 Clinical Trials in Non-Colorectal GI Cancers & #124; REACH-2, KEYNOTE-061, PRODIGE 24 trials
Yung Lyou, MD, UC Irvine Health, talks about 3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24 trials at MOASC 2018 Author: moasc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 16, 2018 Category: Cancer & Oncology Source Type: podcasts

3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24 trials
John P. Fruehauf, MD, UC Irvine Health shares three Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24 trials at MOASC 2018 Author: moasc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
"Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: 'Answering the unmet need in one of the most common types of lymphoma: Its as simple as A-D-C'. Dr Sehn discusses the us... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Making CAR T-cells happen in Europe
John Gribben, of Barts Cancer Institute, London, UK, discusses making CAR T-cells happen in Europe. This video was recorded at the 23rd congress of the European Hematology Association (EHA) 2018 press... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

New drugs for CML: are more to come?
Speaking from the American Society of Oncology (ASCO) 2018, held in Chicago, IL, Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New York, NY, talks about the future uses of asciminib an... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Hypomethylating agents for low risk MDS
Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses extending the use of hypomethylating agents from patients with high risk myelodysplastic syndromes (MDS) to individ... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Bosutinib: a new, safer TKI for frontline CML
The recent FDA approval of bosutinib makes it the fourth inhibitor for the frontline treatment of chronic myeloid leukemia (CML), as Michael Mauro, MD, of Memorial Sloan Kettering Cancer Center, New Y... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Asciminib has the potential to succeed where other TKIs have failed in CML
Tyrosine kinase inhibitors (TKIs) are some of the most successful drugs available for the treatment of a myriad hematological cancers. However, they are not perfect, as patients can relapse or develop... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

IDH inhibitors for AML and MDS
There has been an influx of novel therapies within the field of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Here, Eunice Wang, MD, of Roswell Park Comprehensive Cancer Center, Bu... Author: VJHemOnc Added: 08/15/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other trea... Author: BeaconMedIC Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 15, 2018 Category: Cancer & Oncology Source Type: podcasts

Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer, & RCC
Nataliya Mar, MD, UC Irvine Health, shares her Abstracts were Metastatic Genitourinary Malignancies | Mix of Urothelial Carcinoma, Prostate Cancer, & RCC at MOASC 2018 Author: moasc Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 14, 2018 Category: Cancer & Oncology Source Type: podcasts

SWOG S0226 - for Metastatic Breast Cancer | Additional Fulvestrant and Anastrozole Improves PFS
Rita Sanghvi Mehta, MD, UC Irvine Health, talks about SWOG S0226 - for Metastatic Breast Cancer | Additional Fulvestrant and Anastrozole Improves PFS at MOASC 2018. Author: moasc Added: 08/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 14, 2018 Category: Cancer & Oncology Source Type: podcasts

JAMA Internal Medicine : Evaluating Shared Decision Making for Lung Cancer Screening
Interview with Daniel Scott. Reuland, MD MPH, author of Evaluating Shared Decision Making for Lung Cancer Screening, and Bruno Heleno, MD, PhD, author of Estimation of Overdiagnosis of Lung Cancer in Low-Dose Computed Tomography Screening (Source: JAMA Specialty Journals Author Interviews)
Source: JAMA Specialty Journals Author Interviews - August 13, 2018 Category: General Medicine Source Type: podcasts

PROSPECT: how effective is the new prostvac vaccine against prostate cancer?
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks about prostvac, a novel vaccine his research group is developing to combat prostate cancer. Dr Gulley... Author: VJOncology Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Breast cancer: new advances in personalized medicine and therapeutics
Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN, speaks to us about the different therapies being developed for the treatment of breast cancer. Dr Burris touches ... Author: VJOncology Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Final results of PAKT: capivasertib and paclitaxel for TNBC
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Peter Schmid, MD, PhD, FRCP, from the Barts Cancer Institute, London, UK, discusses the results of their... Author: VJOncology Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts

M7824: a promising novel antibody for HPV-associated cancers
In this video, James Gulley, MD, PhD, FACP, of the National Cancer Institute, Bethesda, MD, speaks to us about the development of M7824, a novel antibody capable of targeting PD-L1 and TGF- simultane... Author: VJOncology Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts

CCGA: plasma cfDNA lung cancer screening
Cell-free (cf)DNA analysis is frequently used in lung cancer to identify therapeutic targets, but there has also been recent interest in using this technology to create a minimally invasive cancer scr... Author: VJOncology Added: 08/13/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 13, 2018 Category: Cancer & Oncology Source Type: podcasts

Results of the OPTIMISMM study for R/R multiple myeloma
Paul Richardson, MD, from Dana-Farber Cancer Institute, Boston, MA, discusses the exciting results of the Phase III OPTIMISMM trial (NCT01734928) that he presented at the American Society of Oncology ... Author: VJHemOnc Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Elderly cancer patients who report symptoms have greater survival
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ral Crdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, describes a... Author: VJHemOnc Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Precision medicine is the future of cancer treatment
Precision, or personalized, medicine has often been regarded as the future of cancer treatment. In this interview, Howard Burris, MD, FACP, FASCO, of the Sarah Cannon Research Institute, Nashville, TN... Author: VJOncology Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

MYMPN: a patient registry removing bias from MPN research
Many clinical trials are skewed towards a certain patient population, resulting in biased data. Here, Ruben Mesa, MD, of UT Health San Antonio Cancer Center, San Antonio, TX, discusses the MYMPN patie... Author: VJHemOnc Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Early MRD negativity predicts depth of response to CAR T-cells in R/R MM
Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, presented results from the CRB-401 trial (NCT02658929) at the 23rd Congress of European Hematology Association (EHA) 2018, held in S... Author: VJHemOnc Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Current treatment landscape in classical MPNs
The treatment landscape for myeloproliferative neoplasms (MPNs) is constantly evolving, as Ruben Mesa, MD, of UT Health San Antonio Cancer Center, San Antonio, TX, explains in this video, recorded at ... Author: VJHemOnc Added: 08/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Does Adjuvant Sunitinib Offer a Benefit after Oligometastasectomy for Kidney Cancer? Highlights from ASCO 2018 (BMIC-052)
Dr. Daniel Goldstein summarizes the findings of a randomized trial assessing the benefit of adjuvant sunitinib following resection of oligometastatic disease in patients with renal cell carcinoma (RCC... Author: BeaconMedIC Added: 08/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 10, 2018 Category: Cancer & Oncology Source Type: podcasts

Johanna C. Bendell, MD - Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Innovative Strategies, and Patient Perspectives on Disease Management
Rethinking Successful Care for Pancreatic Cancer: Therapeutic Sequencing, Innovative Strategies, and Patient Perspectives on Disease Management (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - August 8, 2018 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Is There Still a Role for Cytoreductive Nephrectomy for advanced Kidney Cancer in the Wake of the CARMENA Trial? Highlights from ASCO 2018 (BMIC-051)
Dr. Daniel Goldstein reviews the key data and limitations from the CARMENA trial that re-evaluated the role of nephrectomy in metastatic renal cell carcinoma (RCC), providing insight into how the data... Author: BeaconMedIC Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Can We Effectively Target FGFR with the Novel Agent Erdafitinib for Muscle-Invasive Bladder Cancer? Highlights from ASCO 2018 (BMIC-050)
Dr. Daniel Goldstein reviews highlights in bladder cancer from ASCO 2018, including the novel agent erdafitinib as a treatment targeting fibroblast growth factor receptor (FGFR) alterations in muscle-... Author: BeaconMedIC Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 8, 2018 Category: Cancer & Oncology Source Type: podcasts

Isatuximab: a next-generation monoclonal antibody
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us about isatu... Author: VJHemOnc Added: 08/07/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 7, 2018 Category: Cancer & Oncology Source Type: podcasts

FDA Drug Safety Podcast: FDA warns about increased risk of cancer relapse with long-term use of azithromycin (Zithromax, Zmax) antibiotic after donor stem cell transplant
On August 3, 2018 FDA warned that the antibiotic azithromycin (brand name Zithromax, Zmax) should not be given long-term to prevent a certain inflammatory lung condition in patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant. (Source: FDA Drug Safety Podcasts)
Source: FDA Drug Safety Podcasts - August 6, 2018 Category: Drugs & Pharmacology Authors: U.S. Food and Drug Administration, Center for Drug Evaluation and Research Source Type: podcasts

A breakthrough for oral mucositis management with avisopasem manganese
Locally advanced head and neck cancer is treated with chemotherapy and radiation as standard, with an aim to cure the disease. Unfortunately, this therapy is associated with severe toxicity, primarily... Author: VJOncology Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Assessment and diagnostic workup for NSCLC in 2018
The assessment and diagnostic workup of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) is evolving, as discussed here by Nathan Pennell, MD, PhD, of the Cleveland Clinic, Cl... Author: VJOncology Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

ASCO 2018 bladder and kidney cancer highlights
A variety of highlighly anticipated urological oncology research with great potential was shown at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Here, Neal Shore, M... Author: VJOncology Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Techniques for detecting brain metastases in melanoma
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Melbourne, Australia, di... Author: VJOncology Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Techniques for detecting brain metastases in melanoma
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Grant McArthur, MBBS, BMedSc, PhD, FRACP, of the Peter MacCallum Cancer Centre, Melbourne, Australia, di... Author: VJHemOnc Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

ASCO 2018 bladder and kidney cancer highlights
A variety of highlighly anticipated urological oncology research with great potential was shown at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Here, Neal Shore, M... Author: VJHemOnc Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

Assessment and diagnostic workup for NSCLC in 2018
The assessment and diagnostic workup of newly diagnosed patients with advanced non-small cell lung cancer (NSCLC) is evolving, as discussed here by Nathan Pennell, MD, PhD, of the Cleveland Clinic, Cl... Author: VJHemOnc Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

A breakthrough for oral mucositis management with avisopasem manganese
Locally advanced head and neck cancer is treated with chemotherapy and radiation as standard, with an aim to cure the disease. Unfortunately, this therapy is associated with severe toxicity, primarily... Author: VJHemOnc Added: 08/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 6, 2018 Category: Cancer & Oncology Source Type: podcasts

George D. Demetri, MD - Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors
Making the TRK to Precision Medicine in Cancer: The Promise of Targeting TRK Fusions in Lung, Breast, GI, and Other Tumors (Source: PeerView Press CME/CE International Audio Podcast - Internal Medicine)
Source: PeerView Press CME/CE International Audio Podcast - Internal Medicine - August 3, 2018 Category: Internal Medicine Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Melanoma advancements: immunotherapy in the adjuvant setting
Great strides have been made in the treatment of advanced melanoma; these developments are now being translated into the adjuvant setting. Here, Paolo Ascierto, MD, of the National Cancer Institute of... Author: VJOncology Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Tepotinib in METex14 skipping alteration NSCLC
Enriqueta Felip, MD, PhD, of Vall dHebron University Hospital, Barcelona, Spain, discusses the VISION trial (NCT02864992) of tepotinib for non-small cell lung cancer (NSCLC) patients with MET exon 14... Author: VJOncology Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Palbociclib for platinum-resistant metastatic head and neck cancer
Cetuximab monotherapy is the standard of care for platinum-resistant non-HPV related metastatic head and neck cancer; however, response and survival rates for this treatment are extremely poor. In thi... Author: VJOncology Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Novel combinations for melanoma: PD-1 inhibitor triplet regimens
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Paolo Ascierto, MD, of the National Cancer Institute of Naples, Naples, Italy, discusses some exciting n... Author: VJOncology Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Prostate cancer updates from ASCO 2018
Promising genitourinary cancer updates were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Neal Shore, MD, of Carolina Urologic Research Center, Myrtle ... Author: VJOncology Added: 08/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - August 3, 2018 Category: Cancer & Oncology Source Type: podcasts